Porcine recombinant factor VIII: An additional weapon to handle anti-factor VIII antibodies

Pier Mannuccio Mannucci, Massimo Franchini

Research output: Contribution to journalReview articlepeer-review

Abstract

This review focuses on the use of recombinant porcine factor VIII (FVIII) for the treatment of bleeding episodes in patients with severe haemophilia A complicated by inhibitors and in those with acquired haemophilia A due to the onset of anti-FVIII autoantibodies. We present the main characteristics of recombinant porcine factor VIII (FVIII) and provide a summary of the published results of the clinical studies of this novel recombinant FVIII. There is a special emphasis on how the use of recombinant porcine factor VIII (FVIII) is expected to improve the clinical management of these patients.

Original languageEnglish
Pages (from-to)365-368
Number of pages4
JournalBlood Transfusion
Volume15
Issue number4
DOIs
Publication statusPublished - 2017

Keywords

  • Bleeding
  • Haemophilia A
  • Inhibitors
  • Obizur
  • Porcine recombinant FVIII

ASJC Scopus subject areas

  • Immunology and Allergy
  • Hematology

Fingerprint Dive into the research topics of 'Porcine recombinant factor VIII: An additional weapon to handle anti-factor VIII antibodies'. Together they form a unique fingerprint.

Cite this